177lu-dotatate
Showing 1 - 5 of 5
Neuroendocrine Tumors, Somatostatin Receptor-positive Neuroendocrine Tumor Trial in Madison (Single Photon Emission Computed
Not yet recruiting
- Neuroendocrine Tumors
- Somatostatin Receptor-positive Neuroendocrine Tumor
- Single Photon Emission Computed Tomography/ Computed Tomography (SPECT/CT)
- +3 more
-
Madison, WisconsinUniversity of Wisconsin - Madison
Nov 2, 2023
Neuroendocrine Tumours (NET), Neuroendocrine Carcinomas (NEC) Trial in Spain (177Lu-Dotatate, Nivolumab)
Recruiting
- Neuroendocrine Tumours (NET)
- Neuroendocrine Carcinomas (NEC)
- 177Lu-Dotatate
- Nivolumab
-
Santiago De Compostela, Galicia, Spain
- +4 more
Aug 1, 2022
Neuroendocrine Tumors, Liver-Dominant Metastatic Pancreatic Neuroendocrine Tumors Trial in New York (177Lu-DOTATATE)
Recruiting
- Neuroendocrine Tumors
- Liver-Dominant Metastatic Pancreatic Neuroendocrine Tumors
- 177Lu-DOTATATE
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Jan 19, 2023
Gastro-intestinal Neuroendocrine Tumors Trial in Brussels, Leuven (Interferon alpha-2b, 177Lu-DOTATATE)
Withdrawn
- Gastro-intestinal Neuroendocrine Tumors
- Interferon alpha-2b
- 177Lu-DOTATATE
-
Brussels, Belgium
- +1 more
Apr 4, 2016
Neuroendocrine Tumors Trial in Houston (177Lu-DOTATATE)
Unknown status
- Neuroendocrine Tumors
- 177Lu-DOTATATE
-
Houston, TexasExcel Diagnostics and Nuclear Oncology Center
Aug 3, 2015